i-SENS Holds 3rd Anniversary Event for CareSens Air Launch

i-SENS, a leading biosensor company, held a commemorative event to mark the third anniversary of the launch of its continuous glucose monitor (CGM), CareSens Air.

On the 8th, employees of i-SENS are taking a commemorative photo at the event celebrating the 3rd anniversary of the CareSens Air launch. Photo by i-SENS

According to i-SENS on September 10, the company hosted an internal event on September 8 to celebrate the 3rd anniversary of CareSens Air and shared key achievements related to the product. i-SENS was the first domestic company to launch a CGM and has since completed supply to 29 countries and insurance registration in 10 countries.

Hak Hyun Nam, CEO of i-SENS, expressed his gratitude in a congratulatory address to the employees for their efforts in the development of CareSens Air and the expansion into global markets.

Launched in September 2023, CareSens Air has established itself in a domestic market previously dominated by foreign brands, thanks to its convenience and accuracy. The company has continued to strengthen its product competitiveness by acting on feedback from local medical professionals and users, updating product approvals and improving its features. All processes from research and development to production have been carried out in Korea.

The product is also achieving results in the global market. In the first quarter of this year, sales of connected CGM products increased by 172% compared to the same period last year, and in the second quarter, it achieved its highest quarterly sales to date. The cumulative connected CGM sales for the first half of the year reached 17.8 billion won, of which 10.1 billion won came from overseas markets.

The company plans to step up efforts to capture more of the CGM market by introducing its next-generation product, CareSens Air2. i-SENS is currently conducting clinical trials for FDA approval in the United States, the world’s largest CGM market, and aims to complete both U.S. research clinical trials and China confirmatory trials for the current CareSens Air within this year.

CEO Nam stated, "The past three years have been a time for Korean CGMs to gain a foothold in the domestic market and lay the foundation for entry into overseas markets. Our goal for the next three years is to achieve tangible results in global markets, including the United States, through CareSens Air2."

This content was produced with the assistance of AI translation services.